Angiotensin Receptor-1 Blocker Inhibits Atherosclerotic Changes and Endothelial Disruption of the Aortic Valve in Hypercholesterolemic Rabbits

Journal of the American College of Cardiology

Volumn 49, Issue 13, 2007, Pages 1482-1489

  Arishiro, Kumiko ^a   Hoshiga, Masaaki ^a   Negoro, Nobuyuki ^a   Jin, Denan ^a   Takai, Shinji ^a   Miyazaki, Mizuo ^a   Ishihara, Tadashi ^a   Hanafusa, Toshiaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; MESSENGER RNA; OLMESARTAN; OSTEOPONTIN; TRANSCRIPTION FACTOR RUNX1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA VALVE; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CHOLESTEROL DIET; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HYPERCHOLESTEROLEMIA; LIPID STORAGE; MACROPHAGE; MALE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTIC VALVE; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HYPERCHOLESTEROLEMIA; IMIDAZOLES; MALE; RABBITS; TETRAZOLES;

EID: 33947579076     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.11.043     Document Type: Article

References (36)

1. Lindroos M., Kupari M., Heikkila J., and Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 21 (1993) 1220-1225
2. Bonow R.O., Carabello B., de Leon Jr. A.C., et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 98 (1998) 1949-1984
3. Otto C.M., Kuusisto J., Reichenbach D.D., Gown A.M., and O'Brien K.D. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90 (1994) 844-853
4. Mohler III E.R., Gannon F., Reynolds C., Zimmerman R., Keane M.G., and Kaplan F.S. Bone formation and inflammation in cardiac valves. Circulation 103 (2001) 1522-1528
5. Rajamannan N.M., Subramaniam M., Rickard D., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107 (2003) 2181-2184
6. Bellamy M.F., Pellikka P.A., Klarich K.W., Tajik A.J., and Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 40 (2002) 1723-1730
7. Poggianti E., Venneri L., Chubuchny V., Jambrik Z., Baroncini L.A., and Picano E. Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol 41 (2003) 136-141
8. Demer L.L. Cholesterol in vascular and valvular calcification. Circulation 104 (2001) 1881-1883
9. Mitka M. Researchers probe aortic stenosis: an active, potentially treatable disease process?. JAMA 289 (2003) 2197-2198
10. Rajamannan N.M., and Otto C.M. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 110 (2004) 1180-1182
11. Rajamannan N.M., Subramaniam M., Springett M., et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105 (2002) 2660-2665
12. Novaro G.M., Tiong I.Y., Pearce G.L., Lauer M.S., Sprecher D.L., and Griffin B.P. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104 (2001) 2205-2209
13. Shavelle D.M., Takasu J., Budoff M.J., Mao S., Zhao X.Q., and O'Brien K.D. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359 (2002) 1125-1126
14. Rosenhek R., Rader F., Loho N., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110 (2004) 1291-1295
15. Cowell S.J., Newby D.E., Prescott R.J., et al., Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 (2005) 2389-2397
16. O'Brien K.D., Shavelle D.M., Caulfield M.T., et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106 (2002) 2224-2230
17. O'Brien K.D., Probstfield J.L., Caulfield M.T., et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 165 (2005) 858-862
18. Komori T., Yagi H., Nomura S., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89 (1997) 755-764
19. Helske S., Lindstedt K.A., Laine M., et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 44 (2004) 1859-1866
20. Rajamannan N.M., Sangiorgi G., Springett M., et al. Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis 10 (2001) 371-374
21. Navalkar S., Parthasarathy S., Santanam N., and Khan B.V. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 37 (2001) 440-444
22. Dol F., Martin G., Staels B., et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 38 (2001) 395-405
23. Keidar S., Attias J., Smith J., Breslow J.L., and Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 236 (1997) 622-625
24. Dandona P., Kumar V., Aljada A., et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 88 (2003) 4496-4501
25. Ahmed M.S., Oie E., Vinge L.E., et al. Induction of myocardial biglycan in heart failure in rats-an extracellular matrix component targeted by AT(1) receptor antagonism. Cardiovasc Res 60 (2003) 557-568
26. Tiede K., Stoter K., Petrik C., et al. Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro. Cardiovasc Res 60 (2003) 538-546
27. O'Brien K.D., Olin K.L., Alpers C.E., et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 98 (1998) 519-527
28. O'Brien K.D. Pathogenesis of calcific aortic valve disease. a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 26 (2006) 1721-1728
29. Mohler III E.R. Mechanisms of aortic valve calcification. Am J Cardiol 94 (2004) 1396-1402
30. Hurle J.M., Colvee E., and Fernandez-Teran M.A. The surface anatomy of the human aortic valve as revealed by scanning electron microscopy. Anat Embryol 172 (1985) 61-67
31. Mirzaie M., Meyer T., Schwarz P., Lotfi S., Rastan A., and Schondube F. Ultrastructual alterations in acquired aortic and mitral valve disease as revealed by scanning and transmission electron microscopical investigations. Ann Thorac Cardiovasc Surg 8 (2002) 24-30
32. Oelze M., Mollnau H., Hoffmann N., et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 87 (2000) 999-1005
33. Mohler III E.R., Chawla M.K., Chang A.W., et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 8 (1999) 254-260
34. Walker G.A., Masters K.S., Shah D.N., Anseth K.S., and Leinwand L.A. Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 95 (2004) 253-260
35. Campbell S.E., and Katwa L.C. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 29 (1997) 1947-1958
36. Koike H. New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 87 (2001) 33C-36C